



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/033,109	12/28/2001	Stephen M. Allen	BB1210 USDIV	7649

23906 7590 03/15/2004

E I DU PONT DE NEMOURS AND COMPANY  
LEGAL PATENT RECORDS CENTER  
BARLEY MILL PLAZA 25/1128  
4417 LANCASTER PIKE  
WILMINGTON, DE 19805

[REDACTED] EXAMINER

BUI, PHUONG T

[REDACTED] ART UNIT

[REDACTED] PAPER NUMBER

1638

DATE MAILED: 03/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/033,109	ALLEN ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Phuong T. Bui	1638	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_.
- 2a) This action is **FINAL**.                  2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 22-35 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_ is/are allowed.
- 6) Claim(s) 22-45 is/are rejected.
- 7) Claim(s) \_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 12/28/01.
- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_ .
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_.

## **DETAILED ACTION**

1. Claims 22-35 are pending and are examined in the instant application.

### ***Sequence Listing***

2. Applicant's CRF and paper sequence listing have been entered. However, upon examination of SEQ ID NO:3 and its corresponding amino acid sequence SEQ ID NO:4, it is unclear what region of SEQ ID NO:3 encodes SEQ ID NO:4. Clarification is required.

### ***Information Disclosure Statement***

3. An initialed and dated copies of Applicant's IDS form 1449 is attached to the instant Office action.

### ***Specification***

4. The specification is objected to because of the following: to claim priority benefit, Applicant is required to update the status of parent application 09/384625 in the first line of the specification. Moreover, current US patent policy does not permit the use of hyperlinks in the specification. Such links are directed to an Internet site, the contents of which are subject to change without notice. Therefore, the potential for inclusion of new matter would be a constant problem. See pages 7 and 18, for example.

Correction is required.

### ***Claim Rejections - 35 USC § 112, 2<sup>nd</sup> paragraph***

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 34-35 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 34, it is unclear what size the claimed polynucleotide is. If the claimed polynucleotide containing 30 nucleotides were comprised by another polynucleotide, wouldn't the claimed polynucleotide have to be larger than 30 nucleotides?

Claim 35 is an incomplete method claim because the polypeptide is not expressed.

Clarification and/or correction are required.

***Claim Rejections - 35 USC § 112, first paragraph***

7. Claims 22-24 and 27-35 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for SEQ ID NO:3 and a polynucleotide sequence encoding SEQ ID NO:4, does not reasonably provide enablement for sequences having less than 100% sequence identity with SEQ ID NO:4. Claims reciting less than 100% sequence identity are not enabled because they encompass unspecified base deletions, additions, substitutions, and combinations thereof while retaining ammonium transporter activity. Applicant does not disclose a single sequence having less than 100% sequence identity with SEQ ID NO:4, or provide guidance as to which region(s) of SEQ ID NO:4 must be retained for activity. While skilled in the art can readily make base changes, further guidance is necessary as to what changes would be tolerated. Absent such guidance, one skilled in the art cannot make and use

such sequences without undue experimentation. Accordingly, the claimed invention is not enabled.

8. Claim 34 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. The specification provides support for 30 contiguous nucleotides of SEQ ID NO:3, and does not provide support for any 30 nucleotides. Applicant is invited to point to the page and line number in the specification where support for any 30 nucleotides of a polynucleotide encoding SEQ ID NO:4 can be found. Absent of such support, Applicant is required to cancel the new matter in response to this action.

9. Claims 22-24 and 27-35 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims reciting 80-95% sequence identity lack adequate written description because Applicant does not disclose a representative number of species as encompassed by these claims. The claims encompass mutants and allelic variants and thus imply that structural variants exist in nature, yet no structural variant has been disclosed. The claims also encompass ammonium transporters from other species. The implication is that there is

a gene and a protein other than that disclosed which exists in nature, but the structure thereof is not known. Applicant discloses a single sequence SEQ ID NO:3 isolated from soybean. Thus, there are insufficient relevant identifying characteristics to allow one skilled in the art to predictably determine such mutants, allelic variants and ammonium transporters from other plants and organisms, absent further guidance. Accordingly, there is lack of adequate description to inform a skilled artisan that applicant was in possession of the claimed invention at the time of filing. See Written Description guidelines published in Federal Register/ Vol.66, No. 4/ Friday, January 5, 2001/ Notices; p. 1099-1111.


***Remarks***

10. Claims 25-26 are allowable if rewritten as independent claims. SEQ ID Nos. 3 and 4 are free of the prior art. It is understood by the Office that the Clustal method of alignment recited in the claims uses the default parameters set forth on page 7, lines 15-17 of the specification. The closest prior art teaches a sequence isolated from *Arabidopsis thaliana* having 77.8% sequence identity to SEQ ID NO:4 at the amino acid level using Applicant's Clustal alignment method (Table 4). The same sequence has 80.7% sequence identity to SEQ ID NO:4 using the Office alignment programs and default parameters (Ninnemann et al., EMBO J, Vol. 13, p. 3464-3471, 1994 (Applicant's IDS)).

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong T. Bui whose telephone number is 571-272-0793. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on 571-272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Phuong T. Bui  
Primary Examiner  
Art Unit 1638

3/11/04